Comparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block: Results of a Phase II Clinical Trial

This current phase II clinical trial was to compare the effect and safety of adamgammadex, a new cyclodextrin-based selective relaxant binding agent, with sugammadex to reverse rocuronium-induced neuromuscular block. Patients were randomised to receive adamgammadex (4 or 6 mg kg(−1)) or sugammadex (...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yingying, Zhang, Yujun, Zhu, Zhaoqiong, Huang, Yidan, Zhou, Dachun, Liu, Jingchen, Li, Chaoyu, Chen, Xiangdong, Kang, Dingxin, Wang, Shoushi, Liu, Jin, Liu, Bin, Zhang, Wensheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738056/
https://www.ncbi.nlm.nih.gov/pubmed/36498526
http://dx.doi.org/10.3390/jcm11236951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738056/
https://www.ncbi.nlm.nih.gov/pubmed/36498526
http://dx.doi.org/10.3390/jcm11236951

Ejemplares similares